Table 5 Clinical outcome of patients with hairy cell leukemia-variant

Case #	Treatment	Relapses	FU, m	Status at last follow-up	Concurrent/ secondary neoplasm, m^a
1	Rituximab	1	37	Alive, PD
2	2CDA + Rituximab	No	16	Alive, CR	CMML, concurrent
3	•2CDA •Rituximab •Fludarabine and cytarabine	2	37	Alive, CR
4	Multiple regimens •2CDA + Rituximab •Splenectomy •Pentostatin + Cytoxan + Rituxan •Rituximab + hyper-CVAD	Multiple	88	DOD
5	2CDA + Rituximab	1	74	DOD
6	•2CDA + Rituximab •Splenectomy	No	35	Alive, CR
7	2CDA + Rituximab	No	22	DOC Lung cancer	Lung cancer, 17 m
8	Unknown	Multiple	28	DOC MF	Preexisting myelofibrosis
9	2CDA + Rituximab	Multiple	89	DOC Lung cancer MRD HCL	Melanoma in situ, concurrent Invasive squamous carcinoma, 10 m Lung adenocarcinoma, 92 m
10	On observation only	Persistent	14	Alive, PD
11	2CDA + Rituximab	2	122	DOD
12	•Rituximab •2CDA •Ibrutinib	Multiple	52	Alive, PD
13	Multiple regimens •2CDA •Rituximab •Rituximab + Bendamustine •Ibrutinib	Multiple	254	Alive, PD
14	2CDA + Rituximab	Unknown	NFU	Unknown
15	2CDA + Rituximab	No	31	Alive, CR
16	2CDA	Multiple	151	Alive, PD
17	•Splenectomy •Other therapy unknown	Unknown	NFU	Unknown
18	•Splenectomy •Other therapy unknown	Unknown	NFU	Unknown
19	•Splenectomy •Other therapy unknown	Unknown	NFU	Unknown
20	Unknown	Unknown	NFU	Unknown
21	Unknown	Unknown	NFU	Unknown
22	2CDA + Rituximab	1	14	Alive, PD
23	2CDA + Rituximab	1	20	Alive, PD

2CDA cladribine, CMML chronic myelomonocytic leukemia, CR complete remission, DOC dead of other cause, DOD dead of disease, FU follow-up, hyper-CVAD hyperfractionated chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone, m months, NFU no follow-up, PD persistent disease
^aIndicates months after initial diagnosis for HCLv

Search